HOXD13 and neoplasm: The sPD-1/PD-L1 interaction was specific as demonstrated by the abrogation of sPD-1 binding upon treatment of tumor cells with Atezolizumab and by reduction of PD-L1 MFI indicating that sPD-1might act as a decoy for anti-PD-L1 antibody.